Abstract

BackgroundTargeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance. Preclinical data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clinical activity. We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-positive metastatic breast cancer.MethodsIn this phase I dose-escalation study, patients with trastuzumab-resistant HER2-positive metastatic breast cancer received weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m2) on days 1, 8, 15, and 22 of a 28-day cycle with escalating doses of ganetespib (100 mg/m2, 150 mg/m2, and a third cohort of 125 mg/m2 if needed) on days 1, 8, and 15. Therapy was continued until disease progression or toxicity. The primary objective was to establish the safety and maximum tolerated dose and/or recommended phase II dose (RP2D) of this therapy. The secondary objectives included evaluation of the effects of ganetespib on the pharmacokinetics of paclitaxel, and to make a preliminary assessment of the efficacy of the combination therapy.ResultsDose escalation was completed for the two main cohorts without any observed dose-limiting toxicities. Nine patients received treatment. The median prior lines of anti-HER2 therapy numbered three (range 2–4), including prior pertuzumab in 9/9 patients and ado-trastuzumab emtansine (T-DM1) in 8/9 patients. The most common grade 1/2 adverse events (AEs) were diarrhea, fatigue, anemia, and rash. There were no grade 4 AEs related to ganetespib. The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients). The clinical benefit rate was 44% (4/9 patients). The median progression-free survival was 20 weeks (range 8–55).ConclusionThe RP2D of ganetespib is 150 mg/m2 in combination with weekly paclitaxel plus trastuzumab. The combination was safe and well tolerated. Despite prior taxanes, pertuzumab, and T-DM1, clinical activity of this triplet regimen in this heavily pretreated cohort is promising and warrants further study in HER2-positive metastatic breast cancer.Trial registrationClinicalTrials.gov NCT02060253. Registered 30 January 2014.

Highlights

  • Targeted therapies in Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance

  • We recently reported a single-arm phase II study of single-agent ganetespib in unselected patients with heavily treated metastatic breast cancer who received up to three lines of chemotherapy [19]

  • That study did not meet the prespecified criteria for overall response in the first stage in a heavily pretreated group of patients; there were two confirmed partial response (PR) and six cases of stable disease (SD) in patients with HER2-positive, trastuzumab-refractory metastatic breast cancer that further justified its study for this subtype of breast cancer [19]

Read more

Summary

Introduction

Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. A HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-positive metastatic breast cancer. The greatest clinical activity was reported with tanespimycin (17-AAG) in combination with trastuzumab in trastuzumab-refractory HER2positive metastatic breast cancer with a response rate of 22% and a clinical benefit rate (CBR) of 59% [15, 16]. Another phase I trial of alvespimycin plus trastuzumab reported one partial response (PR) and six cases of stable disease (SD) lasting >6 months in patients with HER2positive metastatic breast cancer [14]. That study did not meet the prespecified criteria for overall response in the first stage in a heavily pretreated group of patients; there were two confirmed PRs and six cases of SD in patients with HER2-positive, trastuzumab-refractory metastatic breast cancer that further justified its study for this subtype of breast cancer [19]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call